FDA draft guidance on addressing misinformation clears White House review


A few months ahead of a potential administration transition, the White House has cleared (with changes) a new question-and-answer draft guidance document focused on “addressing misinformation” about regulated life sciences products. This administrative review is last procedural step before the FDA can publish the document.

Fill out the form to read the full article.

Required *

Copy link
Powered by Social Snap